Commerzbank Ag Reiterates “Buy” Rating for Qiagen NV (QGEN)

Qiagen NV (NASDAQ:QGEN)‘s stock had its “buy” rating restated by analysts at Commerzbank Ag in a note issued to investors on Monday.

QGEN has been the topic of a number of other reports. Zacks Investment Research cut Qiagen NV from a “hold” rating to a “sell” rating in a research note on Tuesday, January 17th. Deutsche Bank AG reiterated a “buy” rating on shares of Qiagen NV in a research note on Tuesday, May 2nd. Jefferies Group LLC reiterated a “hold” rating on shares of Qiagen NV in a research note on Friday, February 3rd. DZ Bank AG reiterated a “neutral” rating on shares of Qiagen NV in a research note on Monday, February 6th. Finally, Barclays PLC reiterated a “buy” rating and issued a $33.00 target price on shares of Qiagen NV in a research note on Friday, May 5th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $28.36.

Analyst Recommendations for Qiagen NV (NASDAQ:QGEN)

Shares of Qiagen NV (NASDAQ:QGEN) opened at 32.52 on Monday. Qiagen NV has a 1-year low of $20.71 and a 1-year high of $32.69. The stock has a 50 day moving average of $29.73 and a 200-day moving average of $29.08. The stock has a market capitalization of $7.40 billion, a P/E ratio of 90.33 and a beta of 1.05.

COPYRIGHT VIOLATION NOTICE: “Commerzbank Ag Reiterates “Buy” Rating for Qiagen NV (QGEN)” was first published by sleekmoney and is owned by of sleekmoney. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://sleekmoney.com/commerzbank-ag-reiterates-buy-rating-for-qiagen-nv-qgen/1828334.html.

Large investors have recently modified their holdings of the stock. First Trust Advisors LP boosted its stake in shares of Qiagen NV by 1.1% in the third quarter. First Trust Advisors LP now owns 1,689,318 shares of the company’s stock worth $46,355,000 after buying an additional 18,182 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Qiagen NV by 43.8% in the third quarter. UBS Asset Management Americas Inc. now owns 29,892 shares of the company’s stock worth $821,000 after buying an additional 9,100 shares in the last quarter. BlackRock Advisors LLC boosted its stake in shares of Qiagen NV by 1.6% in the third quarter. BlackRock Advisors LLC now owns 93,000 shares of the company’s stock worth $2,552,000 after buying an additional 1,438 shares in the last quarter. BlackRock Investment Management LLC boosted its stake in shares of Qiagen NV by 6.5% in the third quarter. BlackRock Investment Management LLC now owns 118,904 shares of the company’s stock worth $3,263,000 after buying an additional 7,205 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Qiagen NV by 3.5% in the third quarter. Teachers Advisors LLC now owns 228,303 shares of the company’s stock worth $6,265,000 after buying an additional 7,781 shares in the last quarter. Institutional investors and hedge funds own 60.68% of the company’s stock.

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

5 Day Chart for NASDAQ:QGEN

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/commerzbank-ag-reiterates-buy-rating-for-qiagen-nv-qgen/1828334.html

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *